Please assess the completion status of the following clinical trial:

Trial Title: Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part I:~* Participant is male or female of non-reproductive potential between 50 and 65 years old.~* Participant is less than 6'5 tall~* Participant is in good health~* Participant has been a non-smoker for at least 10 years~Parts II and III:~* Male or female of non-reproductive potential at least 55 years of age~* Participant is cognitively normal (HE participants), or has probable mild-to moderate AD (AD participants)~* Participant is willing to have an arterial catheter placed in the radial artery (Part II only)~Exclusion Criteria:~Part I:~* Participant has a history of stroke, seizures, or neurological disorder~* Participant has or has a history of any disease or condition, or takes any medication that would interfere with assessment of the tracer or make participation unsafe or unduly uncomfortable~Parts II and III:~* Participant has a history or current evidence of any neurological or neurodegenerative disorder other than AD that is associated with altered cognition~* Participant has or has a history of any disease or condition, or takes any medication that would interfere with assessment of the tracer or make participation unsafe or unduly uncomfortable~* Participant is living in a nursing home or skilled nursing facility

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part I, Healthy Participants (Type: EXPERIMENTAL): Healthy participants will receive a single intravenous (IV) dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part I of the study
- Part II, HE and AD Participants (Type: EXPERIMENTAL): HE and AD participants will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part II of the study
- Part III, HE and AD Participants (Type: EXPERIMENTAL): HE and AD participants will receive two separate IV doses of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part III of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).